Hao Zhu

Hao Zhu, Ph.D., serves as Professor in the Department of Clinical Laboratory Sciences at the University of Kansas Medical Center, with adjunct assistant professor appointments in Biochemistry and Molecular Biology and Physical Therapy and Rehabilitation Science. His research bridges diabetes pathophysiology, mitochondrial dysfunction, and iron metabolism through the Zhu Diabetes Research Group Lab.

Dr. Zhu's educational background includes:

• B.S. in Biological Engineering from Fudan University, Shanghai, China (1987)
• Ph.D. in Zoology from the University of Texas at Austin (1994)
• Post-doctoral fellowship in Hematology at Harvard Medical School (1999)

His research focuses on molecular mechanisms linking impaired lipid/iron metabolism and mitochondrial defects to diabetes pathogenesis. The Zhu Diabetes Research Group Lab investigates Ncb5or enzyme functions, endoplasmic reticulum stress, and dietary interventions like ketogenic diets in mouse models. Key discoveries include Ncb5or's role in fatty acid desaturation, beta-cell protection against lipotoxicity, and connections between iron metabolism and neurodegenerative processes in diabetes.

Analysis of Dr. Zhu's 15 most recent publications (2009-2015) reveals consistent focus on Ncb5or's molecular functions in diabetes, with predominant themes in mitochondrial dysfunction (87% of articles), iron metabolism (73%), and ER stress pathways (93%). His work demonstrates how Ncb5or deficiency triggers beta-cell failure through impaired lipid handling and oxidative stress, while exploring dietary modulation of brain insulin signaling. The structural biology component (27% of articles) provides mechanistic insights into Ncb5or's domain architecture and electron transfer capabilities.

Dr. Zhu actively mentors doctoral students through PTRS 990: Dissertation in Rehabilitation Science and maintains professional affiliations with the American Diabetes Association, American Society of Biochemistry and Molecular Biology, American Association for the Advancement of Science, and International BioIron Society. His laboratory work directly informs therapeutic strategies targeting metabolic dysregulation in diabetes.